



X International Adrenal Cancer Symposium: October 16-18 University of Brescia

Congress Chairmen

Alfredo Berruti

Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, ASST Spedali Civili, Brescia, Italy

Massimo Terzolo

Internal Medicine, Department of Clinical and Biological Sciences, S. Luigi Gonzaga Hospital, University of Turin, 10043, Orbassano, Italy

Introduction

It is with great pleasure that we introduce the 10th International Adrenal Cancer Symposium, set to take place in the historic city of Brescia, Italy, from October 16-18, 2026.

This symposium is a crucial gathering of clinicians, researchers, and allied professionals who are dedicated to studying and treating adrenal malignancies, particularly the extremely rare and challenging Adrenocortical Carcinoma (ACC). By bringing together basic science, translational research, and clinical practice, the program will promote the sharing of latest discoveries, therapeutic innovations, and multidisciplinary care strategies.

The dynamic partnership between the University of Brescia and the University of Turin is central to the organization of this event. These institutions have been cooperating in coordinated research efforts on adrenal neoplasms for a long time.

The decision to host the symposium in Brescia not only honours this elegant and dynamic city in northern Italy, but also offers delegates a rich environment -both academically and culturally- in which to engage.

The meeting aims to bring together multiple facets of adrenal oncology:

Molecular & Genetic Advances: Exploring tumorigenesis in ACC, including biomarkers, genomics, and emerging liquid-biopsy technologies.

Translational Bridges: Linking bench to bedside by emphasizing how mechanistic insights can inform patient care, and how clinical observations can drive research questions.

Clinical Innovation: Surgical strategies, adjuvant therapies, systemic treatments (including mitotane, chemotherapy regimens, novel targeted agents, immunotherapy), and multidisciplinary management of complex cases.

Networking & Collaboration: Fostering international partnerships -between endocrine oncologists, surgeons, radiologists, nuclear medicine specialists, pathologists, and patient advocates- to accelerate progress in this rare field. **Education & Mentoring:** Providing early-career researchers and clinicians with opportunities to engage, present, and learn from established experts in the field of adrenal carcinoma.

Programme

ideA-Z Project in progress S.r.l.

Corso G. Matteotti, 48 - 20081 Abbiategrasso MI Tel. 02.9462227 - Fax 02.87152261 - E-mail info@idea-z.it
Codice Fiscale, P. IVA 03373190960, Rea MI-1670871 - Capitale Sociale € 10.000,00 i.v.

Provider E.C.M. Standard n. 335

Day 1 - October 16th, 2026

13.30 – 14.00: Registration

14.00 – 15.00: Session 1: The Added Value of European Networks for Rare Tumors

Chairpersons: **G. Reimondo, L. Canu**

- ENSAT **Cristina Ronchi**
- EURACAN **Robin Peeters**
- ENDO-ERN **Alberto Pereira**

Discussion

15.00 – 16.30: Session 2: Patient Perspectives

Chairpersons: **A. Pia, G. Frisiani, R. Ambrosini**

16.30 - 17.00 Coffee break

17.00-18.30: Session 3: Proffered Papers

Chairpersons: **F Ceccato, A Stigliano, S. Cassibba**

18.30 – 19.00: Keynote lecture

Chairpersons: **A Berruti, S Cannavò**

AI for drug discovery and development in immunotherapy and targeted therapies **M Garassino**

19.00 – 19.45: Opening Ceremony

Day 2 – October 17th, 2026

08.30 – 10.00: Session 1 - Molecular Heterogeneity of Adrenocortical Tumors

Chairpersons: **Guillaume Assié, F Beuschlein**

08.30 – 08.45: Targeting the Epigenetic-Metabolic Axis: Unlocking New Therapies in ACC

Gary Hammer

08.45 – 09.00: Clearance of senescent macrophages prevents metastatic dissemination in ACC **P Val**

09.00 – 09.15: Cell Fate Programs and Epigenetic Remodeling in ACC

Antonio Marcondes Lerario

09.15 – 09.30: SF-1/NR5A1: A Master Regulator of ACC Malignancy

Enzo Lalli

09.30 – 09.40: The Wnt/ β -Catenin Axis: A Central Driver of ACC Progression

Barbara Altieri

09.40 – 10.00: *Discussion*

10.00 - 10.30: *Coffee Break*

10.30 - 12.00: Session 2 - From Preclinical Models to Translational Research

Chairpersons: **L Poliani, Marco Volante**

10.30 – 10.45: Patient-Derived Models as Tools for ACC Drug Discovery

S Sigala

10.45 – 11.00: Modeling Therapeutic Response: Translational Preclinical Platforms in ACC

K Kiseljak-Vassiliades

11.00 – 11.15: Whole Genome Profiling in Primary and Metastatic ACC: From Biology to Clinical Prediction

A Jouinot

11.15 – 11.15: Preclinical Immunotherapy Approaches in Pediatric ACC:
Insights from TP53 p.R337H Models

E Pinto

11.30 – 11.40: TP53 in ACC: Prognostic Value and Therapeutic Potential

I Bourdeau

11.40 - 12.00: Discussion

12.00 – 12.30: Keynote Lecture

Chairpersons: **W Arlt, E Baudin**

Belzutifan in PPGL: A Model of Precision Oncology in Rare Tumors

C Jimenez

12.30 - 13.30: Lunch & Poster session

13.30 – 15.00: Session 3 - From Bench to Bedside

Chairpersons: **G.Hammer, R Sirianni**

- 13.30 – 13.45:** Evolution from benign to malignant adrenal lesions **Constantine Stratakis**
- 13.45 – 14.00:** The Microbiome–Adrenal Axis: A New Frontier in ACC **Michaela Luconi**
- 14.00 – 14.15:** Unmasking DLK1: A Developmental Regulator Rewired in Adrenocortical Carcinoma and new potential target **Leonardo Guasti**
- 14.15 – 14.30:** Tackling Immune Resistance in ACC: Emerging Strategies **Alfredo Berruti**
- 14.30 – 14.40:** Metabolic Reprogramming in ACC: Opportunities for Targeted Therapy **Vassileios Chortis**
- 14.40 - 15.00:** Discussion
- 15.00 - 15.30** Coffee Break
- 15.30 – 17.00:** Session 4 - Management of Local-Regional Disease
Chairpersons: **Marta Araujo Castro, Maurizio Iacobone**
- 15.30 - 15.45:** R0 resection of ACC: definition and challenges **Matthieu Faron**
- 15.45-16.00:** Hyperthermic Intraperitoneal Chemotherapy: Extending Surgical Boundaries in ACC **Guido Tiberio**
- 16.00 - 16.15:** Neoadjuvant Approaches in ACC: Rationale and Clinical Evidence **Rossella Libè**
- 16.15 - 16.30:** Adjuvant Therapy in ACC: for all, for none, for someone **Massimo Terzolo**
- 16.30 - 16.45:** Focus on: Optimizing Long-Term Mitotane Therapy **Soraya Puglisi**
- 16.45-17.00:** Discussion

Day 3 October 18th

09.00 – 10.40: Session 1 - Management of Metastatic Disease

Chairpersons: **Jerome Bertherat, Mara Giacchè**

09.00 – 09.15: Integrated Approaches to Advanced ACC: Combining Loco-Regional and Systemic Therapies
Jaydira Del Rivero

09.15 – 09.30: Is hypercortisolism a real prognostic factor?
Irina Bancos

09.30 – 09.45: Managing Hormone Excess in Advanced ACC
G.Kaltsas

09.45 – 10.00: Management of Advanced Pediatric Adrenocortical Carcinoma
V Wiegering

10.00 – 10.10: Quality of Life as a Therapeutic Goal in ACC
O Kimpel

10.10 – 10.20: Defining Long-Term Responders in Metastatic ACC
Deborah Cosentini

10.20 - 10.40 Discussion

10.40 – 11.00: Coffee Break

11.00 - 12.20: Session 2 - New Perspectives

Chairpersons: **J Crona, C. Scaroni**

11.00 – 11.15: CAR-T Therapy in ACC: From Concept to Potential Clinical Impact
L Landwehr

11.15 – 11.30: Immunotherapy in ACC: Defining the Right Patient and the Right Time
M Habra

11.30 – 11.45: Precision Medicine in ACC: Harnessing Molecular Profiling
M Fassnacht

11.45 – 11.55: Biomarkers and Predictors of Outcome in Metastatic ACC
P Igaz

11.55 – 12.05: Liquid Biopsy for Real Time Monitoring of ACC Patients
R Toledo

12.05 - 12.20: Discussion

12.20 -12.50: Keynote Lecture

Chairpersons: **Carlo Cappelli, Diego Ferone**

The research on adrenal diseases: a history of successes and failures
A Lacroix

12.50 - 13.50 Lunch



13.50 - 14.50: Session 3 - The Challenges of Clinical Research in Rare Cancers

Chairpersons: ***Manuela Albertelli, G Di Dalmazi***

13.50 – 14.05: Policy and Progress in Ultrarare Cancers

S Moog

14.05 - 14.20: Beyond RCTs: Innovative Trial Designs for Rare Cancers

Massimo Di Maio

14.20 – 14.35: Regulatory and Reimbursement Pathways Without Phase III Evidence

Paolo Casali

14.35 - 14.50: Discussion

14.50 – 16.30: Shaping the Future of Research in ACC

(Presentations and discussions of projects for future multicenter studies)